ClinicalTrials.gg
CompletedNCT00325442Updated Aug 2, 2017Results posted

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

A Phase 3 interventional study of Oral treprostinil (UT-15C) sustained release tablets and Placebo in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 72 sites in 14 countries. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-08-02.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
4th of 44
354 · median 32
Started
2006
with 1 other
Phase 3
14 of 44
1 open now
Registered
3rd of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is one of 2 that started in 2006, is one of 14 in phase 3, and was the 3rd registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits occurred at 4 week intervals for 16 weeks; the key measure of efficacy was the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. One optional substudy was also a part of FREEDOM-C at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 16.

Patients who completed all assessments for 16-weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).

03

Conditions studied

  • Pulmonary Hypertension

Browse trials for

Keywords

  • Pulmonary Arterial Hypertension
04

In context

Pulmonary Arterial Hypertension Reclassified

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

This study's enrollment of 354 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 12 and 70 years of age, inclusive.
  • Body weight at least 45 kg (approximately 100 pounds).
  • PAH that is either idiopathic/heritable (including PAH associated with appetite suppressant/toxin use); PAH associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); PAH associated with collagen vascular disease; or PAH associated with .
  • Baseline 6-minute walk distance between 150 and 450 meters, inclusive.
  • Currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days.
  • Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.
  • Reliable and cooperative with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Nursing or pregnant.
  • Received a prostacyclin within the past 30 days.
  • PAH due to conditions other than noted in the above inclusion criteria.
  • History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.
  • Use of an drug within 30 days of Baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
354 participants (actual)

Study arms

  • Active comparator
    Active

    Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.

    Drug: Oral treprostinil (UT-15C) sustained release tablets

  • Placebo comparator
    Placebo Arm

    Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 16, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

    Time frame: Baseline and 16 Weeks

Secondary outcomes

  1. Borg Dyspnea Score

    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).

    Time frame: Baseline and 16 Weeks

  2. Clinical Worsening Assessment

    Definition of clinical worsening required one of the following: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. ≥ 20% decrease in 6-minute walk distance from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5I, prostacyclin).

    Time frame: Baseline and 16 Weeks

  3. Dyspnea-Fatigue Index

    The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.

    Time frame: Baseline and 16 Weeks

  4. World Health Organization Functional Classification for PAH

    Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.

    Time frame: Week 16

  5. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

    Time frame: Baseline and 12 weeks

  6. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

    Time frame: Baseline and 8 weeks

  7. Six Minute Walk Distance (6MWD)

    Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

    Time frame: Baseline and 4 weeks

  8. Change in Symptoms of PAH From Baseline to Week 16

    Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 16. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom. The outcome data describes the change in severity values from Baseline to Week 16 for each defined symptom of PAH.

    Time frame: Baseline and 16 weeks

08

Results

Posted Jun 10, 2013

Participant flow

354 subjects were randomized with 350 subjects receiving a dose of study drug and subsequently analyzed from 20 October 2006 to 17 September 2008 at 70 sites across the United States, Canada, Europe, Israel, and Australia.

Participant flow — Overall Study
MilestonePlacebo ArmActive
Started176174
Completed167153
Not completed921

Outcome measures

PrimarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 16, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

Time frame:
Baseline and 16 Weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlacebo ArmActive
6MWD at Baseline362.5 (302.0 to 400.0)362.5 (304.0 to 397.0)
6MWD at Week 16367.0 (283.0 to 420.5)381.0 (323.0 to 420.0)
Change in 6MWD from Baseline to Week 164.8 (-22.0 to 35.5)14.5 (-10.0 to 47.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.072 · Hodges-lehmann: 11.0 · 95% CI 0 to 22
SecondaryBorg Dyspnea Score

The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).

Time frame:
Baseline and 16 Weeks
Reported as:
Mean · units on a scale
Borg Dyspnea Score
units on a scalePlacebo ArmActive
Borg dyspnea score at Baseline4.26 ± 2.254.22 ± 2.24
Borg dyspnea score at Week 164.64 ± 2.624.18 ± 2.59
Change in Borg dyspnea score from BL to Wk 160.38 ± 2.06-0.03 ± 2.13
Statistical analysis
  • Placebo Arm vs Active · Wilcoxon rank-sum test · p = 0.062 · Hodges-lehmann (h-l): 0.0 · 95% CI -1.0 to 0.0
SecondaryClinical Worsening Assessment

Definition of clinical worsening required one of the following: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. ≥ 20% decrease in 6-minute walk distance from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5I, prostacyclin).

Time frame:
Baseline and 16 Weeks
Reported as:
Number · participants
Clinical Worsening Assessment
participantsPlacebo ArmActive
Clinical Worsening Assessment128
Statistical analysis
  • Placebo Arm vs Active · Fisher Exact · p = 0.491
SecondaryDyspnea-Fatigue Index

The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.

Time frame:
Baseline and 16 Weeks
Reported as:
Mean · units on a scale
Dyspnea-Fatigue Index
units on a scalePlacebo ArmActive
Dyspnea-fatigue index at Baseline5.5 ± 2.25.7 ± 2.1
Dyspnea-fatigue index at Week 165.1 ± 2.55.7 ± 2.5
Change in dyspnea-fatigue index from BL to Wk 16-0.4 ± 1.90.0 ± 1.9
Statistical analysis
  • Placebo Arm vs Active · Wilcoxon sum-rank test · p = 0.011 · Hodges-lehmann (h-l): 0.0 · 95% CI 0.0 to 1.0
SecondaryWorld Health Organization Functional Classification for PAH

Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.

Time frame:
Week 16
Reported as:
Number · participants
World Health Organization Functional Classification for PAH
participantsPlacebo ArmActive
WHO Class I12
WHO Class II4858
WHO Class III114103
WHO Class IV1311
SecondarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

Time frame:
Baseline and 12 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlacebo ArmActive
6MWD at Baseline362.5 (302.0 to 400.0)362.5 (304.0 to 397.0)
6MWD at Week 12366.4 (280.5 to 424.0)378.0 (320.0 to 425.0)
Change in 6MWD from Baseline to Week 125.8 (-23.5 to 29.5)16.5 (-15.0 to 51.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.015 · Hodges-lehmann (h-l): 13.0 · 95% CI 3.0 to 23.0
SecondarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

Time frame:
Baseline and 8 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlacebo ArmActive
6MWD at Baseline362.5 (302.0 to 400.0)362.5 (304.0 to 397.0)
6MWD at Week 8368.5 (294.5 to 416.0)379.0 (310.0 to 415.0)
Change in 6MWD from Baseline to Week 87.0 (-22.0 to 30.5)15.0 (-9.0 to 42.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.051 · Hodges-lehmann: 9.0 · 95% CI 0.0 to 18.0
SecondarySix Minute Walk Distance (6MWD)

Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.

Time frame:
Baseline and 4 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD)
metersPlacebo ArmActive
6MWD at Baseline362.5 (302.0 to 400.0)362.5 (304.0 to 397.0)
6MWD at Week 4363.0 (299.0 to 410.5)370.5 (312.0 to 410)
Change in 6MWD from Baseline to Week 42.1 (-17.5 to 24.5)5.5 (-8.0 to 31.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.238 · Hodges-lehmann ( h-l): 4 · 95% CI -2.4 to 12.0
Post-hocSix Minute Walk Distance (6MWD) by Baseline 6MWD Quartiles: Quartile 1 (126-302 Meters)
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Baseline 6MWD Quartiles: Quartile 1 (126-302 Meters)
metersPlacebo ArmActive
6MWD at Baseline247.0 (191.0 to 288.0)255.0 (204.0 to 289.0)
6MWD at Week 16241.0 (141.0 to 286.0)265.0 (189.0 to 325.0)
Change in 6MWD from Baseline to Week 16-5.6 (-39.0 to 16.0)17.0 (-13.0 to 43.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.121 · Hodges-lehmann (h-l): 24 · 95% CI 0 to 45
Post-hocSix Minute Walk Distance (6MWD) by Baseline 6MWD Quartile: Quartile 2 (303 - 362 Meters)
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Baseline 6MWD Quartile: Quartile 2 (303 - 362 Meters)
metersPlacebo ArmActive
6MWD at Baseline332.0 (323.0 to 354.0)339.0 (323.5 to 350.5)
6MWD at Week 16348.0 (300.0 to 376.0)359.0 (329.5 to 400.5)
Change in 6MWD from Baseline to Week 1612.0 (-22.0 to 37.0)17.0 (-0.4 to 53.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.069 · Hodges-lehmann (h-l): 15 · 95% CI -7 to 41
Post-hocSix Minute Walk Distance (6MWD) by Baseline 6MWD Quartile: Quartile 3 (363 - 397 Meters)
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Baseline 6MWD Quartile: Quartile 3 (363 - 397 Meters)
metersPlacebo ArmActive
6MWD at Baseline385.0 (378.0 to 390.0)383.0 (376.0 to 390.0)
6MWD at Week 16388.0 (358.0 to 429.0)396.0 (370.0 to 417.0)
Change in 6MWD from Baseline to Week 166.5 (-22.0 to 43.0)13.0 (-8.0 to 44.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.889 · Hodges-lehmann (h-l): 4 · 95% CI -15 to 24
Post-hocSix Minute Walk Distance (6MWD) by Baseline 6MWD Quartile: Quartile 4 (398 - 450 Meters)
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Baseline 6MWD Quartile: Quartile 4 (398 - 450 Meters)
metersPlacebo ArmActive
6MWD at Baseline425.5 (410.0 to 440.0)425.0 (412.0 to 430.0)
6MWD at Week 16442.0 (411.0 to 468.0)438.5 (395.0 to 483.0)
Change in 6MWD from Baseline to Week 1615.0 (-6.0 to 49.0)15.0 (-20.0 to 59.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.966 · Hodges-lehmann (h-l): 0 · 95% CI -23 to 24
Post-hocChange in Six Minute Walk Distance (6MWD) From Baseline in Subjects Who Received Oral Treprostinil by Last Study Drug Dose and Reason for Discontinuation

In general, the dose of study drug was increased in 0.5 mg increments every 3 days, in the absence of dose-limiting drug-related AEs, to ensure the subject received the optimal clinical dose throughout the study.

Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Change in Six Minute Walk Distance (6MWD) From Baseline in Subjects Who Received Oral Treprostinil by Last Study Drug Dose and Reason for Discontinuation
metersLess Than 1 mg or Discontinuation Due to Adverse Events1.25 - 3.25 mg3.5 - 16 mg
Change in Six Minute Walk Distance (6MWD) From Baseline in Subjects Who Received Oral Treprostinil by Last Study Drug Dose and Reason for Discontinuation3.8 (-8.0 to 26.0)18.0 (-3.0 to 56.0)34.0 (3.0 to 52.0)
Post-hocSix Minute Walk Distance (6MWD) by Lowest Dose Strength Available at Randomization: Smallest Dose Available 1 mg
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Lowest Dose Strength Available at Randomization: Smallest Dose Available 1 mg
metersPlacebo ArmActive
6MWD at Baseline348.0 (282.0 to 385.0)349.0 (311.0 to 380.0)
6MWD at Week 16350.0 (243.0 to 431.0)379.0 (324.7 to 405.0)
Change in 6MWD from Baseline to Week 1615.0 (-26.0 to 55.0)22.0 (5.0 to 45.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.853 · Hodges-lehmann (h-l): 5 · 95% CI -16 to 28
Post-hocSix Minute Walk Distance (6MWD) by Lowest Study Drug Dose Strength Available at Randomizaiton: Dose Strength 0.5 mg
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Lowest Study Drug Dose Strength Available at Randomizaiton: Dose Strength 0.5 mg
metersPlacebo ArmActive
6MWD at Baseline366.0 (302.0 to 410.0)370.0 (297.0 to 411.0)
6MWD at Week 16370.0 (283.0 to 430.0)375.5 (301.0 to 439.5)
Change in 6MWD from Baseline to Week 167.0 (-19.0 to 30.0)7.0 (-19.0 to 46.5)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.327 · Hodges-lehmann (h-l): 7 · 95% CI -7 to 21
Post-hocSix Minute Walk Distance (6MWD) by Lowest Study Drug Dose Strength Available at Randomization: Study Drug Dose 0.25 mg
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Lowest Study Drug Dose Strength Available at Randomization: Study Drug Dose 0.25 mg
metersPlacebo ArmActive
6MWD at Baseline374.0 (319.0 to 408.0)384.0 (306.0 to 405.0)
6MWD at Week 16374.0 (320.0 to 399.0)398.0 (340.0 to 438.0)
Change in 6MWD from Baseline to Week 16-1.0 (-30.0 to 12.0)21.0 (-7.0 to 78.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.085 · Hodges-lehmann (h-l): 29.5 · 95% CI 1 to 73
Post-hocSix Minute Walk Distance (6MWD) by Background PAH Therapy: ERA
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Background PAH Therapy: ERA
metersPlacebo ArmActive
6MWD at Baseline382.0 (325.0 to 403.0)372.0 (325.0 to 398.0)
6MWD at Week 16377.0 (303.0 to 423.0)385.0 (306.4 to 422.0)
Change in 6MWD from Baseline to Week 16-3.0 (-22.0 to 30.0)4.0 (-16.0 to 40.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.615 · Hodges-lehmann (h-l): 5 · 95% CI -12 to 24
Post-hocSix Minute Walk Distance (6MWD) by Background PAH Therapy: PDE5-I
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Background PAH Therapy: PDE5-I
metersPlacebo ArmActive
6MWD at Baseline360.0 (302.0 to 397.0)348.0 (296.0 to 390.0)
6MWD at Week 16357.0 (318.0 to 424.0)373.0 (307.0 to 411.0)
Change in 6MWD from Baseline to Week 168.0 (-31.0 to 47.0)23.0 (-3.0 to 47.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.230 · Hodges-lehmann (h-l): 17 · 95% CI -6 to 40
Post-hocSix Minute Walk Distance (6MWD) by Background PAH Therapy: ERA and PDE5-I
Time frame:
Baseline and 16 weeks
Reported as:
Median · meters
Six Minute Walk Distance (6MWD) by Background PAH Therapy: ERA and PDE5-I
metersPlacebo ArmActive
6MWD at Baseline351.5 (290.0 to 400.0)358.5 (300.0 to 412.0)
6MWD at Week 16359.2 (243.0 to 418.0)381.0 (325.0 to 425.0)
Change in 6MWD from Baseline to Week 168.0 (-20.0 to 35.0)14.5 (-13.0 to 47.0)
Statistical analysis
  • Placebo Arm vs Active · ANCOVA · p = 0.209 · Hodges-lehmann (h-l): 10 · 95% CI -6 to 28
SecondaryChange in Symptoms of PAH From Baseline to Week 16

Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 16. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom. The outcome data describes the change in severity values from Baseline to Week 16 for each defined symptom of PAH.

Time frame:
Baseline and 16 weeks
Reported as:
Mean · units on a scale
Change in Symptoms of PAH From Baseline to Week 16
units on a scalePlacebo ArmActive
Change in fatigue symptoms0.0 ± 0.00.01 ± 0.10
Change in dypsnea symptoms0.00 ± 0.00-0.01 ± 0.09
Change in edema symptoms0.00 ± 0.00-0.06 ± 0.10
Change in dizziness symptoms0.00 ± 0.00-0.16 ± 0.11
Change in syncope symptoms0.00 ± 0.00-0.10 ± 0.09
Change in chest pain symptoms0.00 ± 0.00-0.09 ± 0.11
Change in orthopnea symptoms0.00 ± 0.00-0.20 ± 0.10

Adverse events

Collected over Adverse events were recorded throughout the 16 week study which was conducted between October 2006 and September 2008.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Arm—33/176 (18.8%)157/176 (89.2%)
Active—32/174 (18.4%)173/174 (99.4%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPlacebo ArmActive
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders8/1769/174
right ventricular failureCardiac disorders2/1766/174
renal failure acuteRenal and urinary disorders0/1763/174
syncopeGeneral disorders3/1762/174
dyspneaRespiratory, thoracic and mediastinal disorders3/1761/174
atrial flutterCardiac disorders1/1762/174
chest painCardiac disorders2/1760/174
hypotensionVascular disorders2/1760/174
nauseaGastrointestinal disorders2/1760/174
pneumoniaRespiratory, thoracic and mediastinal disorders2/1760/174
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlacebo ArmActive
headacheNervous system disorders65/176150/174
nauseaGastrointestinal disorders60/176112/174
diarrheaGastrointestinal disorders48/176106/174
flushingVascular disorders27/17685/174
vomitingGastrointestinal disorders14/17676/174
pain in jawMusculoskeletal and connective tissue disorders21/17675/174
pain in extremityMusculoskeletal and connective tissue disorders17/17654/174
dizzinessEar and labyrinth disorders28/17630/174
fatigueGeneral disorders17/17625/174
myalgiaMusculoskeletal and connective tissue disorders6/17624/174

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo ArmActiveTotal
<=18 years538
Between 18 and 65 years149151300
>=65 years222042
Age, Continuous
Age, Continuous(years)Placebo ArmActiveTotal
Mean49.5 ± 13.351.1 ± 12.350.3 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo ArmActiveTotal
Female140148288
Male362662
Distance Traversed (meters) During Six Minute Walk Test at Baseline
Distance Traversed (meters) During Six Minute Walk Test at Baseline(meters)Placebo ArmActiveTotal
Mean345.4 ± 75.5346.1 ± 71.4345.7 ± 73.4
Baseline WHO Functional Classification
Baseline WHO Functional Classification(participants)Placebo ArmActiveTotal
WHO Functional Class I123
WHO Functional Class II314172
WHO Functional Class III139127266
WHO Functional Class IV549
PAH Etiology
PAH Etiology(participants)Placebo ArmActiveTotal
Idiopathic / familial PAH119113232
PAH associated with collagen vasular disease434992
PAH associated wtih congenital heart defect111122
PAH associated with HIV infection314
Background PAH Therapy
Background PAH Therapy(participants)Placebo ArmActiveTotal
ERA5155106
PDE5-I434588
ERA and PDE5-I8274156
09

Study locations

72 sites
  • University of Alabama-Birmingham
    Birmingham, Alabama 35294, United States
  • Arizona Pulmonary Specialist
    Phoenix, Arizona 85013, United States
  • University of Arizona Health Science Center
    Tucson, Arizona 85724, United States
  • West Los Angeles VA Healthcare Center
    Los Angeles, California 90073, United States
  • Stanford University, Pulmonary and Critical Care
    Palo Alto, California 94305, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • University of California-San Francisco
    San Francisco, California 94143, United States
  • Harbour-UCLA Medical Center
    Torrance, California 90502, United States
  • The Children's Hospital
    Aurora, Colorado 80218, United States
  • Pulmonary Hypertension Clinic
    Aurora, Colorado 80262, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Iowa Health Care
    Iowa, Iowa 52242, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • John's Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University Hospital
    Saint Louis, Missouri 63110, United States
  • Columbia Presbyterian Medical Center
    New York, New York 10032, United States
  • Mary M Parkes Center for Asthma, Allergy and Pulmonary Care
    Rochester, New York 14643, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Legacy Clinic Northwest
    Portland, Oregon 97239, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • UT Southwestern
    Dallas, Texas 75235, United States
  • Baylor College of Medicine, Pulmonary & Critical Care
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Intermountain Medical Center
    Murray, Utah 84143, United States
  • Inova Transplant Center
    Fairfax, Virginia 22042, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Heart Care Associates
    Milwaukee, Wisconsin 53215, United States
  • St. Vincent's Hospital
    Sydney, New South Wales, Australia
  • The Prince Charles Hospital
    Brisbane, Australia
  • The Alfred Hospital
    Melbourne, Australia
  • Royal Perth Hospital
    Perth, Australia
  • Medizinische Universität Innsbruck
    Innsbruck, Austria
  • Universitaet Wien
    Wien, Austria
  • Hospital Erasme
    Brussels, Belgium
  • University Hospital Gasthuisberg
    Leuven, Belgium
  • Respiratory Research
    Calgary, Alberta, Canada
  • Vancouver Coastal Health Respiratory Clinic
    Vancouver, British Columbia V5Z 3J5, Canada
  • Lab London Health Sciences Center
    London, Ontario N6A 4G5, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • SMBD Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Hospital Cavale Blanche
    Brest, France
  • Hospital Antoine Beclere
    Clamart, France
  • Hospital Claude Huriez
    Lille Cedex, France
  • Hôpital Louis Pradel
    Lyon, France
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • Mater Misericordiae University Hospital Ltd
    Dublin, Ireland
  • Hadassah Ein-Kerem Medical Center
    Jerusalem, Israel
  • Rabin Medical Center
    Petach Tikva, Israel
  • Tel Hashomer Medical Center
    Ramat Gan, Israel
  • Universita degli Studi Bologna
    Bologna, Italy
  • Universita "La Sapienza" Roma
    Rome, Italy
  • Hospital Vrije Universiteit
    Amsterdam, Netherlands
  • National Tuberculosis and Lung Disease Research Institute
    Warsaw, Poland
  • Hospital Clinic of Barcelona
    Barcelona, Spain
  • Hospital Valle Hebron
    Barcelona, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
  • Papworth Hospital
    Cambridge, United Kingdom
  • Western Infirmary
    Glasgow, United Kingdom
  • Royal Free Hospital
    London, United Kingdom
  • Freeman Hospital
    Newcastle, United Kingdom
10

References and documents

Publications

  • Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galie N. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012 Dec;142(6):1383-1390. doi: 10.1378/chest.11-2212. PubMed 22628490 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Sep 2008 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2006
First posted
May 12, 2006
Start
Oct 2006
Primary completionActual
Sep 2008
CompletionActual
Dec 2010
Results first posted
Jun 10, 2013
Last update
Aug 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00325442
Responsible party
Sponsor
First posted
May 12, 2006
Start date
Oct 2006
Primary completion
Sep 2008
Completion
Dec 2010
Results posted
Jun 10, 2013
Last update
Aug 2, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion